Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2004

Filing Date
Filed February 16, 2005
Period End
December 31, 2004
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 16, 2005. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported a net loss of $45.8 milliona, or $1.26 per share, for 2004, compared with a net loss of $30.3 million, or $0.93 per share, in 2003.

Total revenues were $85.2 millionb in 2004, down from $139.1 million in 2003, as sponsored development revenue fell from $96.7 million to $27.2 million with the winding down of the Phase III indiplon program. Milestones and license fees rose to $57.6 million, including $20.5 million in Pfizer milestones tied to Phase III studies. The accumulated deficit reached $278.0 million at year-end 2004.

The company's lead product candidate is indiplon, a non-benzodiazepine GABA-A agonist for insomnia, partnered with Pfizer. Neurocrine submitted new drug applications for indiplon immediate release capsules in October 2004 and modified release tablets in November 2004. In December 2004 the FDA did not accept the IR NDA due to difficulties navigating the electronic filing, and the company withdrew the MR application.

Neurocrine plans to refile the IR NDA at the end of the first quarter or beginning of the second quarter of 2005 and the MR NDA in the second quarter of 2005. Pfizer is to fund a 200-person sales force starting in 2005, and the filing states that the company expects indiplon to be commercially available by 2006. At December 31, 2004, cash, cash equivalents and short-term investments totaled $301.1 millionc, down from $453.2 million a year earlier, after a $50.0 million payment to Wyeth for the indiplon royalty stream and operating losses.

Operating cash flow was negative $100.0 milliond in 2004. The company stated that existing capital resources, interest income and future alliance payments are expected to be sufficient for at least the next 12 months.

Key Highlights

  1. Net loss of $45.8 million ($1.26 per share) in 2004, versus $30.3 million ($0.93 per share) in 2003
  2. Total revenues of $85.2 million in 2004, down from $139.1 million in 2003, mainly due to lower sponsored development revenue as the indiplon Phase III program wound down
  3. Indiplon NDA for immediate release capsules was not accepted by the FDA in December 2004 due to electronic navigation difficulties; the company plans to refile the IR NDA in early Q2 2005 and the MR NDA in Q2 2005
  4. Pfizer collaboration covers indiplon development and commercialization, including funding of a 200-person sales force beginning in 2005 and a $100 million upfront payment received in 2003
  5. Cash, cash equivalents and short-term investments of $301.1 million at December 31, 2004, down from $453.2 million, including a $50.0 million payment to Wyeth for the indiplon royalty stream
  6. Accumulated deficit of $278.0 million at December 31, 2004, and the company does not expect to be profitable from product sales or royalties in 2005
  7. Pipeline of 12 programs, including eight in clinical development, spanning CRF antagonists, GnRH antagonists, altered peptide ligands for multiple sclerosis and Type 1 diabetes, and urocortin 2 for heart failure

Frequently Asked Questions

  1. What is the main product candidate and where is it in the regulatory process?

    The lead product candidate is indiplon, a treatment for insomnia. Neurocrine submitted NDAs for indiplon IR capsules in October 2004 and MR tablets in November 2004. The FDA did not accept the IR NDA in December 2004 due to electronic navigation difficulties, and the company withdrew the MR NDA. Refiling is planned for early Q2 2005 (IR) and Q2 2005 (MR).

  2. Why did revenue decline in 2004?

    Total revenues fell to $85.2 million from $139.1 million. Sponsored development revenue dropped to $27.2 million from $96.7 million as the Phase III indiplon program wound down. This was partly offset by $57.6 million in milestones and license fees, including $20.5 million in Pfizer milestones for Phase III studies.

  3. How is the company funding its operations?

    Neurocrine relies on collaborations with Pfizer, GlaxoSmithKline, Wyeth and Eli Lilly, as well as public and private stock offerings. Cash, cash equivalents and short-term investments were $301.1 million at year-end 2004. Management believes these resources, together with interest income and future alliance payments, will be sufficient for at least the next 12 months, though it may need additional funding.

  4. What are the key risks highlighted in the filing?

    Key risks include FDA approval of indiplon and the timing of NDA refiling, dependence on Pfizer for indiplon funding and commercialization (Pfizer may terminate on 180 days' notice), reliance on third-party contract manufacturers, a history of losses with no product revenue to date, competition from established insomnia drugs such as Ambien and Sonata, and the need for additional capital.

  5. What does the company expect in terms of expenses going forward?

    The company expects R&D expenses to increase modestly in 2005 as non-indiplon programs grow, offsetting the wind-down of the indiplon Phase III program. General and administrative costs are expected to rise significantly in 2005 as the sales force is built, with that cost offset by Pfizer funding. The company also expects to begin expensing employee stock options under SFAS 123R starting in 2005.